vs
Side-by-side financial comparison of MODIV INDUSTRIAL, INC. (MDV) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $11.1M, roughly 1.2× MODIV INDUSTRIAL, INC.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 11.0%, a 64.7% gap on every dollar of revenue.
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
MDV vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $13.7M |
| Net Profit | $1.2M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 45.8% | -86.5% |
| Net Margin | 11.0% | 75.7% |
| Revenue YoY | -5.6% | — |
| Net Profit YoY | -22.0% | 179.1% |
| EPS (diluted) | $0.02 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $13.7M | ||
| Q3 25 | $11.7M | $19.1M | ||
| Q2 25 | $11.8M | $8.1M | ||
| Q1 25 | $11.8M | $2.9M | ||
| Q4 24 | $11.7M | — | ||
| Q3 24 | $11.7M | — | ||
| Q2 24 | $11.4M | — | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $1.2M | $10.4M | ||
| Q3 25 | $1.0M | $-16.3M | ||
| Q2 25 | $-2.0M | $-15.8M | ||
| Q1 25 | $829.0K | $-13.3M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-587.0K | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $3.7M | — |
| Q4 25 | 45.8% | -86.5% | ||
| Q3 25 | 41.4% | -10.1% | ||
| Q2 25 | 9.8% | -177.7% | ||
| Q1 25 | 40.2% | -472.7% | ||
| Q4 24 | 45.4% | — | ||
| Q3 24 | 42.0% | — | ||
| Q2 24 | 44.6% | — | ||
| Q1 24 | 55.6% | — |
| Q4 25 | 11.0% | 75.7% | ||
| Q3 25 | 9.0% | -85.4% | ||
| Q2 25 | -17.1% | -196.0% | ||
| Q1 25 | 7.0% | -452.7% | ||
| Q4 24 | 13.3% | — | ||
| Q3 24 | -5.0% | — | ||
| Q2 24 | 11.6% | — | ||
| Q1 24 | 31.1% | — |
| Q4 25 | $0.02 | $-3.74 | ||
| Q3 25 | $0.00 | $-0.11 | ||
| Q2 25 | $-0.32 | $-0.16 | ||
| Q1 25 | $-0.01 | $-0.18 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 24 | $0.03 | — | ||
| Q1 24 | $0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $137.5M |
| Total DebtLower is stronger | $261.5M | — |
| Stockholders' EquityBook value | $162.7M | $35.3M |
| Total Assets | $476.5M | $154.7M |
| Debt / EquityLower = less leverage | 1.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $137.5M | ||
| Q3 25 | $8.3M | $103.8M | ||
| Q2 25 | $5.8M | $121.6M | ||
| Q1 25 | $6.2M | $89.1M | ||
| Q4 24 | $11.5M | — | ||
| Q3 24 | $6.8M | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | $18.4M | — |
| Q4 25 | $261.5M | — | ||
| Q3 25 | $279.7M | — | ||
| Q2 25 | $279.7M | — | ||
| Q1 25 | $279.7M | — | ||
| Q4 24 | $279.8M | — | ||
| Q3 24 | $279.7M | — | ||
| Q2 24 | $279.7M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | $162.7M | $35.3M | ||
| Q3 25 | $164.8M | $-8.1M | ||
| Q2 25 | $165.6M | $7.1M | ||
| Q1 25 | $171.1M | $10.7M | ||
| Q4 24 | $190.1M | — | ||
| Q3 24 | $186.3M | — | ||
| Q2 24 | $187.0M | — | ||
| Q1 24 | $188.0M | — |
| Q4 25 | $476.5M | $154.7M | ||
| Q3 25 | $499.6M | $133.7M | ||
| Q2 25 | $498.9M | $133.8M | ||
| Q1 25 | $506.8M | $103.7M | ||
| Q4 24 | $507.8M | — | ||
| Q3 24 | $507.4M | — | ||
| Q2 24 | $519.5M | — | ||
| Q1 24 | $522.5M | — |
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 1.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.0M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | 12.34× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.0M | $-2.0M | ||
| Q3 25 | $4.1M | $-17.5M | ||
| Q2 25 | $3.9M | $-14.5M | ||
| Q1 25 | $3.0M | $29.0M | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $5.1M | — | ||
| Q2 24 | $4.7M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 12.34× | -0.19× | ||
| Q3 25 | 3.95× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.68× | — | ||
| Q4 24 | 11.72× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.55× | — | ||
| Q1 24 | 0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
